Filspari Dosage

Generic name: SPARSENTAN 200mg
Dosage form: tablet, film coated
Drug class: Miscellaneous cardiovascular agents

Medically reviewed by Drugs.com. Last updated on Sep 4, 2024.

2.1 General Considerations

Prior to initiating treatment with FILSPARI, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists (ERAs).

2.2 Monitoring

Initiate treatment with FILSPARI only after measuring aminotransferase levels and total bilirubin. Avoid initiation in patients with elevated aminotransferases greater than 3 times ULN. Continue required monitoring monthly for the first 12 months after initiation or restarting following an interruption due to elevated transaminases, then every 3 months during treatment with FILSPARI.

Initiate treatment with FILSPARI in patients who can become pregnant only after confirmation of a negative pregnancy test. Pregnancy tests are required monthly during treatment and one month after discontinuation of treatment with FILSPARI.

2.3 Recommended Dosage

Initiate treatment with FILSPARI at 200 mg orally once daily. After 14 days, increase to the recommended dose of 400 mg once daily, as tolerated. When resuming treatment with FILSPARI after an interruption, consider titration of FILSPARI, starting at 200 mg once daily. After 14 days, increase to the recommended dose of 400 mg once daily.

2.4 Administraion

Instruct patient to swallow tablets whole with water prior to the morning or evening meal.
Maintain the same dosing pattern in relationship to meals.
If a dose is missed, take the next dose at the regularly scheduled time. Do not take double or extra doses.

2.5 Dosage Adjustment for Aminotransferase Elevations

If aminotransferase levels increase, adjust monitoring and treatment plan according to Table 1.

Do not resume treatment in patients who have experienced clinical symptoms of hepatotoxicity or in patients whose hepatic enzyme levels and bilirubin have not returned to pretreatment levels.

Table 1: Dosage Adjustment and Monitoring in Patients Developing Aminotransferase Elevations Greater Than 3 Times ULN
ALT = alanine aminotransferase; AST = aspartate aminotransferase; INR = international normalized ratio; ULN = upper limit of normal.
ALT/AST levels	Treatment and monitoring recommendations
Greater than 3 times and less than or equal to 8 times ULN	Confirm elevation with a repeat measure. If confirmed, interrupt treatment, and monitor aminotransferase levels and bilirubin at least weekly, and INR as needed, until the levels return to pretreatment values and the patient is asymptomatic. Do not resume treatment if any of the following occurs without other cause found: ALT or AST greater than 3 times ULN and total bilirubin greater than 2 times ULN or INR greater than 1.5 ALT or AST greater than 3 times ULN, with symptoms of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (greater than 5% eosinophils) ALT or AST greater than 5 times ULN for more than 2 weeks If treatment is resumed, initiate FILSPARI at 200 mg once daily, with reassessment of hepatic enzyme levels and bilirubin within 3 days. Close monitoring is required in these patients.
Greater than 8 times ULN	Stop treatment permanently if no other cause found.